This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
« Back
Page 1 of 573

Alcobra Applies Revisionist History to ADHD Drug Study Analysis

By Adam Feuerstein

Alcobra disclose new details about the phase III study of attention-deficit hyperactivity disorder drug candidate which contradict results announced by the company in an Oct. 6 press release.

09:26AM 10/23/14

Regulus Gets Seat at Hep C Table With Today's Impressive Drug Results

By Adam Feuerstein

But you're getting way ahead of the facts if you think Regulus has a game-changing hepatitis C therapy in its grasp already. There's a lot more questions to be answered.

11:52AM 10/22/14

Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results

By Adam Feuerstein

My question about Achillion and ACH-3422 question sparked a robust Twitter debate, which I've reproduced below with some additional comments and explanatory notes.

08:39AM 10/22/14

Some Potential Targets for Shire to Buy With $1.6B in Free Money

By Adam Feuerstein

Shire isn't obligated to spend AbbVie's money, but it's no fun speculating about earned interest. Which drug companies might be takeout targets for Shire?

09:29AM 10/21/14

Ebola Stocks May Be Overpriced as Fundamentals Outweigh Fear

By Adam Feuerstein

Ebola stocks have soared in recent weeks but a closer look at fundamentals may serve as a reality check for investors playing the story.

06:10AM 10/21/14

First Detailed Look at Celgene Crohn's Disease Pill Impresses

By Adam Feuerstein

As a pill, Celgene's GED-031 (also known as mongersen) has the potential to become a preferred Crohn's therapy over injectable drugs like Abbvie's top-selling Humira.

10:56AM 10/20/14

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

07:05AM 10/17/14

Brainstorm CEO Offers Investors a Frank Outlook for ALS Therapy

By Adam Feuerstein

Given the usual hype surrounding small-cap biotechs, Brainstorm CEO Tony Fiorino is refreshingly candid about the company's chances of developing a stem-cell treatment to counter ALS symptoms.

08:30AM 10/16/14

FDA Approves Competing Lung Disease Drugs From Roche and Boehringer

By Adam Feuerstein

U.S. patients suffering from idiopathic pulmonary fibrosis finally gain access to Esbriet, approved for use in Europe since early 2011.

04:07PM 10/15/14

Gilead Sciences Falls Amid Worries Over Hep-C Drug Price

By Adam Feuerstein

It's one thing for small-cap biotech stocks to trade horribly, but healthcare investors take notice when shares of Gilead Sciences GILD take a turn south.

10:53AM 10/14/14

« Back
Page 1 of 573

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,725.72 +264.40 1.61%
S&P 500 1,954.58 +27.47 1.43%
NASDAQ 4,456.2810 +73.4340 1.68%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs